NIS Foundations - Shielding India
- Initiated as Expanded Programme on Immunization (EPI) in 1978.
- Transformed into Universal Immunization Programme (UIP) in 1985.
⭐ UIP was launched nationwide in 1985, a pivotal public health milestone for India.
- Primary Goal: Reduce morbidity & mortality from Vaccine Preventable Diseases (VPDs) in children & pregnant women.
- UIP, India's National Immunization Program, delivers vaccines as per the National Immunization Schedule (NIS) under NHM (National Health Mission).
"""
NIS Schedule - Age-Wise Armor
⭐ Birth: BCG, OPV0, HepB (<24h).
| Age | Vaccine(s) | Dose | Route | Site |
|---|---|---|---|---|
| Birth | BCG | 0.05ml (<1m) / 0.1ml (>1m) | ID | LUA |
| OPV-0 | 2 drops | Oral | ||
| HepB-Birth | 0.5ml | IM | ALT (L) | |
| 6 Weeks | OPV-1 | 2 drops | Oral | |
| Pentavalent-1 (DPT+HepB+HiB) | 0.5ml | IM | ALT (L) | |
| Rota-1 | 5 drops / 2.5ml | Oral | ||
| fIPV-1 | 0.1ml | ID | RUA | |
| PCV-1 | 0.5ml | IM | ALT (R) | |
| 10 Weeks | OPV-2 | 2 drops | Oral | |
| Pentavalent-2 | 0.5ml | IM | ALT (L) | |
| Rota-2 | 5 drops / 2.5ml | Oral | ||
| 14 Weeks | OPV-3 | 2 drops | Oral | |
| Pentavalent-3 | 0.5ml | IM | ALT (L) | |
| Rota-3 | 5 drops / 2.5ml | Oral | ||
| fIPV-2 | 0.1ml | ID | RUA | |
| PCV-2 | 0.5ml | IM | ALT (R) | |
| 9-12 Months | MR-1 | 0.5ml | SC | RUA |
| JE-1 (SA) | 0.5ml | SC | LUA | |
| PCV-B | 0.5ml | IM | ALT (L) | |
| 16-24 Months | MR-2 | 0.5ml | SC | RUA |
| DPT-B1 | 0.5ml | IM | ALT (L)/UA | |
| OPV-B | 2 drops | Oral | ||
| JE-2 (SA) | 0.5ml | SC | LUA | |
| 5-6 Years | DPT-B2 | 0.5ml | IM | UA |
| 10 Years | Td | 0.5ml | IM | UA |
| 16 Years | Td | 0.5ml | IM | UA |
| Pregnant Women | Td-1 (EP) | 0.5ml | IM | UA |
| Td-2 (4wpT1) | 0.5ml | IM | UA | |
| Td-B (2Td prg <3y) | 0.5ml | IM | UA | |
| """ |
Vaccine Profiles - Key Player Stats
📌 Live Vaccines: BCG, OPV, MR, Rota.
- BCG (Live Att.): Store +2°C to +8°C (light protect). Contra: Symptomatic HIV/SCID. AEFI: BCG lymphadenitis.
- OPV (Live Att. Oral): Store -20°C (long); +2°C to +8°C (short). Contra: Immunodeficiency (self/contact). AEFI: VAPP.
- IPV (Killed Inj.): Store +2°C to +8°C (No Freeze). Contra: Neomycin/Strep. anaphylaxis. AEFI: Local reactions.
- Pentavalent (Mixed): Store +2°C to +8°C (No Freeze). Contra: Progressive neuro disorder. AEFI: Fever, HHE. (See quote).
- MR/MMR (Live Att.): Store +2°C to +8°C; use recon. in 4-6h. Contra: Pregnancy, severe immunodeficiency. AEFI: Fever, rash.
- Rotavirus (Live Att. Oral): Store +2°C to +8°C. Contra: Intussusception Hx, SCID. AEFI: Mild GI upset, intussusception risk.
- PCV (Conjugate): Store +2°C to +8°C (No Freeze). Contra: Anaphylaxis. AEFI: Local reactions, fever.
- TT/Td (Toxoid): Store +2°C to +8°C (No Freeze). Contra: Anaphylaxis, Arthus rxn. AEFI: Local ("tetanus arm").
⭐ Pentavalent components: Diphtheria (Toxoid), Pertussis (wP), Tetanus (Toxoid), HepB (Recombinant), Hib (Conjugate).
Program Pillars - Reach & Vigilance
- Mission Indradhanush (MI): Aims to ↑ full immunization coverage.
- Targets: Children < 2 yrs & pregnant women.
- Intensified MI (IMI) for focused areas.
⭐ Target beneficiaries of Mission Indradhanush are children up to 2 years of age and all pregnant women.
- Pulse Polio Program: Mass campaigns; India polio-free since March 2014. Surveillance continues.
- Cold Chain: System for vaccine storage & transport at optimal temperatures.
- Equipment: ILR, Deep Freezer, Cold Box, Vaccine Carrier.
- VVM: 4 stages; discard at stage 3 or 4.

- AEFI (Adverse Event Following Immunization): Any untoward medical occurrence post-immunization.
- Reporting: Mandatory for all AEFIs.
- Serious AEFI: Death, disability, hospitalization, cluster (group of events).
High‑Yield Points - ⚡ Biggest Takeaways
- Universal Immunization Programme (UIP), launched in 1985, provides free vaccines against 12 major diseases.
- Mission Indradhanush (MI) focuses on rapidly increasing full immunization coverage for children and pregnant women.
- Pentavalent vaccine protects against Diphtheria, Pertussis, Tetanus, Hepatitis B, and Hib.
- India's polio endgame strategy includes Injectable Polio Vaccine (IPV) alongside bivalent Oral Polio Vaccine (bOPV).
- Measles-Rubella (MR) vaccine aims to eliminate measles and control Congenital Rubella Syndrome (CRS).
- Newer vaccines like Rotavirus (RVV) and Pneumococcal Conjugate (PCV) are progressively introduced nationwide based on disease burden.
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app